The acute pain crisis in sickle cell disease: What can be done to improve outcomes?
- PMID: 38553339
- DOI: 10.1016/j.blre.2024.101194
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?
Abstract
The acute pain crisis (APC) is the commonest complication of sickle cell disease (SCD). Severe episodes may require treatment in hospital with strong opioid analgesic drugs, combined with additional supportive care measures. Guidelines for APC management have been produced over the past two decades gathering evidence from published studies, expert opinion, and patient perspective. Unfortunately, reports from multiple sources indicate that guidelines are often not followed, and that acute care in emergency departments and on acute medical wards is suboptimal. It is important to understand what leads to this breakdown in health care, and to identify evidence-based interventions which could be implemented to improve care. This review focuses on recently published articles as well as information about on-going clinical trials. Aspects of care which could potentially make a difference to patient experience include availability and accessibility of individual care plans agreed between patient and treating specialist, innovative means of delivering initial opioids to reduce time to first analgesia, and availability of a specialist unit away from the ED, where expert care can be delivered in a more compassionate environment. The current evidence of improved outcomes and health economic advantage with these interventions is inadequate, and this is hampering their implementation into health care systems.
Keywords: Ambulatory care; Analgesia; Crisis; Opioids; Pain; Sickle.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest PT: Advisory boards and committees: Pfizer, Vertex, Novo Nordisk, Agios. Research funding: Vertex PLC. KA: Advisory boards and honoraria: Pfizer, Vertex, Novartis. SK: No conflicts of interest. LA: No conflicts of interest. SH: No conflicts of interest. CB: No conflicts of interest. S S-S: No conflicts of interest. SL: Consultancy and honoraria: Sanius health, Kite Gilead, Vertex, GBT/Pfizer.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous